

OncoMed Pharmaceuticals Inc  
Form 8-K  
April 17, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 17, 2017

ONCOMED PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-35993	38-3572512
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification Number)

800 Chesapeake Drive

Redwood City, California 94063

(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (650) 995-8200

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934

Edgar Filing: OncoMed Pharmaceuticals Inc - Form 8-K

(§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 2.02. Results of Operations and Financial Condition.

On April 17, 2017, OncoMed Pharmaceuticals, Inc. (the “Company”) announced its cash and short-term investment balance for the quarter ended March 31, 2017. The full text of the press release issued in connection with the announcement (the “Press Release”) is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is located on the Company’s website at [www.oncomed.com](http://www.oncomed.com) under “Investors – Press Releases.”

The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

Item 8.01. Other Events.

On April 17, 2017, in the Press Release, the Company also announced top-line results from the Company’s randomized 145-patient Phase 2 PINNACLE clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) in combination with etoposide plus either cisplatin or carboplatin chemotherapy in previously untreated patients with extensive-stage small cell lung cancer, as well as a conference call/webcast to review these results. The Company further reported in the Press Release that it will discontinue enrollment in the Phase 1b clinical trial of brontictuzumab (anti-Notch1, OMP-52M51) in combination with trifluridine/tipiracil (Lonsurf®) in third-line colorectal cancer patients. The first, third, and fifth paragraphs of the Press Release are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.	Description
99.1	Press release dated April 17, 2017 entitled “OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints”

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 17, 2017    ONCOMED PHARMACEUTICALS, INC.

By: /s/ Alicia J. Hager  
Alicia J. Hager, J.D., Ph.D.

Senior Vice President and General Counsel

---

EXHIBIT INDEX

Exhibit

No. Description

99.1 Press release dated April 17, 2017 entitled “OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints”